Spiriva Sales Data
| Rank 13 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Spiriva U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 13 | $746,766 | -0.16% | 3,056 | -9.61% |
| Q3 2013 | 13 ( 1) |
$747,962 | 3.45% | 3,381 | -7.14% |
| Q2 2013 | 12 | $722,993 | -0.42% | 3,641 | 0.89% |
| Q1 2013 | 12 | $726,057 | 3.39% | 3,609 | -1.50% |
| Q4 2012 | 12 ( 2) |
$702,246 | 4.83% | 3,664 | 5.56% |
| Q3 2012 | 14 (3) |
$669,882 | 1.31% | 3,471 | 1.34% |
| Q2 2012 | 17 (2) |
$661,211 | 0.21% | 3,425 | 0.76% |
| Q1 2012 | 19 (3) |
$659,818 | 8.12% | 3,399 | 5.62% |
| Q4 2011 | 22 (1) |
$610,265 | 6.93% | 3,218 | 2.48% |
| Q3 2011 | 23 | $570,706 | -1.46% | 3,140 | -2.45% |
| Q2 2011 | 23 | $579,164 | 3.82% | 3,219 | 2.29% |
| Q1 2011 | 23 | $557,860 | n/a | 3,147 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
